Emerging strategies and novel therapeutics for patients with primary metastatic and relapsed bone and soft tissue sarcoma

Program Agenda

7:30 – 8 a.m. 
Registration/ Breakfast

8 – 8:30 a.m. 
Introduction/Overview | Bhuvana A. Setty, MD (NCH)

8:30 – 9 a.m. 
LSD1 in Ewing sarcoma: what a long strange trip it’s been! 
Stephen A. Lessnick, MD, PhD (NCH)

9 – 9:30 a.m. 
Targeting osteosarcoma by manipulating the signals that osteosarcoma cells use to manipulate the lungs | Ryan D. Roberts, MD, PhD (NCH)

9:30 – 10 a.m. 
Disrupting the paradigm of osteosarcoma therapy-novel players in a new order 
Nicola Mason, DVM, BVetMed (UPenn)

10 – 10:15 a.m. 
BREAK

10:15 – 10:45 a.m. 
Approaches to pediatric sarcoma diagnosis | Michael A. Arnold, MD, PhD (NCH)

10:45 – 11:30 a.m. 
Emerging strategies for the treatment of advanced rhabdomyosarcoma 
Abha Gupta, MD (Toronto)

11:30 a.m. – 12:30 p.m. 
Osteosarcoma: Learning from the past to move forward 
Katherine A. Janeway, MD (Boston)

12:30 – 1:30 p.m. 
LUNCH

1:30 – 2 p.m. 
Sarcoma biomarkers hiding in plain sight: Identifying targetable patient subsets 
James L. Chen, MD (OSUCCC)

2 – 2:30 p.m. 
Local control surgery in the metastatic patient 
Thomas Scharschmidt, MD (OSUCCC)

2:30 – 3 p.m. 
New developments in our understanding of desmoids 
Raphael Pollock, MD, PhD (OSUCCC)
3 – 3:30 p.m.  Radiation treatment for pediatric sarcoma: Current management and future directions  
Joshua Palmer, MD (OSUMC)

3:30 – 3:45 p.m.  BREAK

3:45 – 4:15 p.m.  Approaches to relapse Ewing sarcoma | Lars Wagner, MD (Duke)

4:15 – 4:45 p.m.  Emerging applications of hypofractionated radiotherapy for the treatment of metastatic and relapsed sarcomas  
Ralph Vatner, MD, PhD (UC Health)

4:45 – 5:15 p.m.  Am I hot or not? The importance of immunologic temperature in sarcoma immunotherapies  
Timothy P. Cripe, MD, PhD (NCH)

5:15 – 5:30 p.m.  Closing Remarks/Discussion/Adjourn